A new market study reveals that the global Calcify Uremic Arteriolopathy (Cua) Drug Market is poised for significant expansion in the coming years, propelled by the rising prevalence of End-Stage Renal Disease (ESRD) and the critical need for effective treatment for this rare but devastati